Check-cap receives fda ide approval for pivotal study of c-scan®

Isfiya, israel, march 15, 2021 /prnewswire/ -- check-cap ltd. (the "company" or "check-cap") (nasdaq: chek), (nasdaq: chekz), a clinical stage medical diagnostics company advancing the development of c-scan® , the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (crc), today announced that the u.s. food and drug administration (fda) has approved the company's investigational device exemption (ide) application, permitting check-cap to begin a pivotal study of c-scan in the u.s. c-scan is intended for candidates who are at average-risk for crc and who are poor candidates for colonoscopy or decline colonoscopy, or who had an incomplete optical colonoscopy.
CHEK Ratings Summary
CHEK Quant Ranking